BDWM
BMY.RT

Brewin Dolphin Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,150
Closed -$2.17K – 328
2020
Q4 		$2.17K Buy
3,150
+85
+3% +$181 ﹤0.01% 273
2020
Q3 		$6.9K Hold
3,065
– – ﹤0.01% 245
2020
Q2 		$11K Buy
+3,065
New +$11.1K ﹤0.01% 246
2020
Q1 		– Sell
-400
Closed -$1.2K – 215
2019
Q4 		$1.2K Buy
+400
New +$1.04K ﹤0.01% 195

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Brewin Dolphin Wealth Management's BMY.RT Position: Q1 2021 in Review

Brewin Dolphin Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 3,150 shares — an estimated $2.17K sold.

Brewin Dolphin Wealth Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $11K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Brewin Dolphin Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Brewin Dolphin Wealth Management sold 3,150 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $2.17K.
  • Brewin Dolphin Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Brewin Dolphin Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $11K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Brewin Dolphin Wealth Management's 13F filing for Q1 2021, filed 9 Nov 2023.